CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Jul. 31, 2017	Jul. 31, 2016
Operating Expenses:
Research and development	$ 422,294	$ 467,382
General and administrative	1,174,547	1,435,186
Total Operating Expenses	1,596,841	1,902,568
Operating Loss	(1,596,841)	(1,902,568)
Other Income/(Expense):
Impairment of patents (Note 4)		1,165,864
Interest expense	(743,101)	(418,500)
Changes in fair value of contingent purchase consideration (Note 14)	(61,822,197)
Impairment of goodwill (Note 14)	(13,380,377)
Change in fair value of derivative liabilities	709,917	263,823
Net (Loss)	(76,832,599)	(3,223,109)
Net (loss) attributable to noncontrolling interests	(6,816,405)
Net (Loss) Available to Common Stockholders	$ (70,016,194)	$ (3,223,109)
Net (Loss) Per Common Share (Note 10) - Basic	$ (70.92)	$ (3.69)
Net (Loss) Per Common Share (Note 10) - Diluted	$ (70.92)	$ (3.69)
Shares Used to Compute (Loss) per Share (Note 10) - basic and diluted	987,288	873,309
Other Comprehensive Income
Net (Loss)	$ (70,016,194)	$ (3,223,109)
Change in foreign currency translation adjustments	(15,722)	(9,865)
Comprehensive Loss Available to Common Stockholders	$ (70,031,916)	$ (3,232,974)